RTP Mobile Logo
Select Publications

Chung HC et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 2020;15(4):618-27. Abstract

Drapkin BJ, Rudin CM. Advances in small-cell lung cancer (SCLC) translational research. Cold Spring Harb Perspect Med 2020;a038240. Abstract

Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-29. Abstract

Owonikoko TK et al. YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival. ASCO 2020;Abstract 9019.

Paz-Ares LG et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929-39. Abstract

Paz-Ares LG et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. ASCO 2020;Abstract 9002.

Poirier JT et al. New approaches to SCLC therapy: From the laboratory to the clinic. J Thor Oncol 2020;15(4):520-40. Abstract

Ready NE et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort. J Thor Oncol 2020;15(3):426-35. Abstract

Rudin CM et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020;38(21):2369-79. Abstract

Rudin CM et al. Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data. Nature Rev Cancer 2019;19(5):289-97. Abstract

Sabari JK et al. Unravelling the biology of SCLC: Implications for therapy. Nature Rev Clin Oncol 2017;14(9):549-61. Abstract

Sen T et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov 2019;9(5):646-61. Abstract

Thomas TS et al. Evaluation of the incidence of pneumonitis in United States veterans with non-small cell lung cancer receiving durvalumab following chemoradiation. ASCO 2020;Abstract 9034.

Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract

von Pawel J et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32(35):4012-9. Abstract

Weiskopf K et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 2016;126(7):2610-20. Abstract